share_log

Virpax Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933

SEC announcement ·  Apr 18 16:22
Summary by Moomoo AI
Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on April 18, 2024, for a proposed public offering of its securities. The offering includes shares of common stock, common warrants to purchase additional shares, and pre-funded warrants in lieu of common stock for certain investors. The pre-funded warrants are immediately exercisable at a nominal exercise price. The common warrants are exercisable immediately upon issuance and will expire five years from the date of issuance. The offering is being conducted on a best-efforts basis by A.G.P./Alliance Global Partners as the sole placement agent. The proceeds from the offering are intended to be used for working capital and other general corporate purposes, including the payment of a settlement agreement obligation. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'VRPX'. The offering is expected to close on or about May 25, 2024, subject to customary closing conditions.
Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on April 18, 2024, for a proposed public offering of its securities. The offering includes shares of common stock, common warrants to purchase additional shares, and pre-funded warrants in lieu of common stock for certain investors. The pre-funded warrants are immediately exercisable at a nominal exercise price. The common warrants are exercisable immediately upon issuance and will expire five years from the date of issuance. The offering is being conducted on a best-efforts basis by A.G.P./Alliance Global Partners as the sole placement agent. The proceeds from the offering are intended to be used for working capital and other general corporate purposes, including the payment of a settlement agreement obligation. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'VRPX'. The offering is expected to close on or about May 25, 2024, subject to customary closing conditions.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Doc 5

Doc 6

Doc 7

Doc 8

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more